Industrialized GMP Production of CD34(+) Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.

Hénon P, Kowalczyk M, Aries A, Vignon C, Trébuchet G, Lahlil R

DOI: 10.1007/s12015-022-10373-5
Published: 2022 Jun
Container: Stem cell reviews and reports
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12015-022-10373-5,
  title = {Industrialized GMP Production of CD34(+) Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.},
  author = {Hénon P and Kowalczyk M and Aries A and Vignon C and Trébuchet G and Lahlil R},
  year = {2022},
  journal = {Stem cell reviews and reports},
  doi = {10.1007/s12015-022-10373-5},
  url = {https://doi.org/10.1007/s12015-022-10373-5}
}

RIS

TY  - JOUR
TI  - Industrialized GMP Production of CD34(+) Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.
AU  - Hénon P
AU  - Kowalczyk M
AU  - Aries A
AU  - Vignon C
AU  - Trébuchet G
AU  - Lahlil R
PY  - 2022
JO  - Stem cell reviews and reports
DO  - 10.1007/s12015-022-10373-5
UR  - https://doi.org/10.1007/s12015-022-10373-5
ER  -

APA

P, H., M, K., A, A., C, V., G, T., & R, L. (2022). Industrialized GMP Production of CD34(+) Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.. Stem cell reviews and reports. https://doi.org/10.1007/s12015-022-10373-5

Source records

pubmed · retrieved 2026-09-27T10:14:46.230Z